United States Assisted Reproductive Technology Market Assessment, By Product, By Technology, By Patient Type, By End-user, Region, Opportunities and Forecast, 2018-2032F

United States assisted reproductive technology (ART) market is projected to witness a CAGR of 5.40% during the forecast period 2025-2032, growing from USD 6.28 billion in 2024 to USD 9.56 billion in 2032. The market's growth can be attributed to the increasing preference for delaying parenthood, rising cases of infertility due to changing lifestyle and eating habits and increasing awareness about the different fertility solutions available in the market. As per the estimates of the Center for Disease Control and Prevention, approximately 13.4% of women of ages 15-49 have impaired fertility.

The increasing number of same-sex couples, along with increasing preference for single parenthood in the United States, are further propelling the reliance on ART in the country. Egg donation and sperm banking have become accepted practices as third-party reproductive modes, and gestational surrogacy has gained legal and social acceptance in several states across the country. Fertility clinics are expanding their networks of donor banks and surrogate-matching services to accommodate the distinctive requirements of diverse patient populations. The ethical and legal intricacies associated with any of these arrangements, however, do present some challenges; nevertheless, transparency in these areas is on the rise due to the framework of standardization to ensure the protection of both patients and donors alike.

Increasing Investments Boost Market Growth

Investments in ART are enabling the expansion of fertility clinics, improving treatment accessibility, and advancements in medical technologies. Availability of capital supports research and development activities, resulting in higher success rates for artificial insemination and IVF, among other procedures. Additionally, investments also allow fertility clinics to modernize and expand their facilities, allowing them to provide high-quality care to the patient population.

In May 2023, Morgan Health (a JPMorgan Chase & Co. business unit) invested USD 25 million in Kindbody, a leading fertility clinic network, to expand the accessibility of high-quality reproductive healthcare services for employees across the United States to combat the growing threat of infertility.

Technological Advancements Support Market Expansion

Growing emphasis on technological innovations is driving the market's growth and bolstering the availability of technological solutions such as time-lapse embryo imaging, artificial intelligence-assisted embryo selection, non-invasive preimplantation genetic testing (niPGT), and advanced cryopreservation techniques. Artificial intelligence and machine learning tools are becoming increasingly useful in identifying the most viable embryos for implantation, thereby reducing cycle failure rates and improving live birth outcomes. Robot-assisted minimally invasive procedures make egg retrievals and embryo transfer more comfortable for patients and enable faster recovery. These technological improvements are making ART more accessible, efficient, and personalized, thus allowing the market players to expand their customer base.

Additionally, leading ART service providers are also focusing on collaborations to ensure the delivery of advanced technologies and services. For instance, in October 2024, Cryoport, Inc. partnered with TMRW Life Sciences, Inc. to provide fertility clinics with advanced solutions for secure transportation and management of the specimen.

Fertility Clinics Hold Major Market Share

Fertility clinics hold a major share of the market in the United States as they offer a broad range of fertility services, including fertility ART procedures, donor services, and counseling. The specialized workforce, state-of-the-art laboratories, and individual treatment protocols make clinics the preferred option for patients. Many clinics have cooperative agreements and are part of growing fertility networks supported by private equity firms, thus leading to greater consolidation and expansion. Such consolidation allows for greater service scalability, enhanced quality assurance, and regional and national brand marketing, allowing them to expand their market presence. Additionally, various fertility clinics are also focusing on developing digital patient portals, using mobile applications for tracking treatment adherence, and artificial intelligence-based cycle management platforms to make the treatment journey smoother, thus allowing the segment's expansion. Furthermore, various fertility clinics are also focusing on partnerships and collaborations to ensure the provision of advanced treatment solutions to the patient population.

For instance, in April 2024, First Fertility, one of the largest fertility networks in the United States, expanded its nationwide presence by partnering with Fertility & Surgical Associates of California (FSAC), a leading fertility practice known for advanced treatments. The collaboration aims to combine First Fertility's comprehensive, patient-centered care model with FSAC's expertise and advanced technology, enhancing access to state-of-the-art reproductive healthcare in the region.

Impact of the U.S. Tariffs on United States Assisted Reproductive Technology (ART) Market

The recently imposed tariffs have resulted in significant challenges for the ART market in the United States. The tariffs, aimed at boosting domestic manufacturing, have resulted in supply chain disruptions and increased costs for raw materials within the industry.

The tariffs are expected to bolster the costs of essential equipment and consumables for ART, including specialized laboratory equipment, cryopreservation media, and incubators. These increased costs are expected to cause hindrances for small and medium-sized fertility clinics that may struggle to absorb the increased expenses. Thus, affecting the affordability of the treatment solutions, limiting access to ART.

Key Players Landscape and Outlook

The market's key players are focusing on launching next-generation solutions to bolster the effectiveness of reproductive technologies. For instance, in July 2023, Thermo Fisher Scientific Inc. launched the Ion AmpliSeq Polyploidy Kit and the Ion ReproSeq PGT-A Kit for supporting preimplantation genetic testing-aneuploidy (PGT-A), commonly used to inform intracytoplasmic sperm injection (ICSI) and in vitro fertilization (IVF) research. PGT-A testing is used to identify chromosomal abnormalities in embryos. Such launches are expected to enhance the probability of successful pregnancies and improve reproductive health outcomes for future generations by providing researchers with deeper genomic insights.